Compare Tidewater Inc (TDW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Tidewater Inc trades at $83.01 (market cap $4.12B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Tidewater Inc is more actively traded (718,273 versus 2,060,842). Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 27 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TDW | TVTX | |
|---|---|---|
Market Cap | $4.12B | $5.02B |
Volume | 718,273 | 2,060,842 |
Sector | Energy | Health |
52-Week High | $100.61 | $67.52 |
52-Week Low | $47.29 | $26.79 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $4.16B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $86.97, up 0.6% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though recent quarterly earnings have missed expectations. Positive developments include the completion of the Wilson Sons Ultratug acquisition in August 2026 and a significant $503.2M investment from BlackRock.
The stock offers potential upside to the price target, driven by operational strength and strategic acquisitions. Key risks include earnings volatility, competitive pressures in the energy sector, and exposure to geopolitical tensions affecting day rates. Investor sentiment is mixed, with 30.77% of analysts rating it a buy amid recent insider selling and institutional accumulation.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
